Product image of Letybo (Botulinum Toxin Type A) supplied by GNH India

Letybo

Active Ingredient:
Botulinum Toxin Type A
Origin:
EU

Letybo (Botulinum Toxin Type A)

Botulinum Toxin Type A, the active ingredient in Letybo, is a neuromuscular blocking agent presented as a sterile injectable for intramuscular use. It is employed to induce temporary muscle paralysis in therapeutic settings such as movement‑disorder and spasticity management.

GNH India supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Croma Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Botulinum Toxin Type A is used to treat disorders involving abnormal muscle overactivity.

  • Cervical dystonia: reduces painful neck muscle contractions.
  • Blepharospasm: relieves involuntary eyelid closure.
  • Chronic migraine: decreases frequency of migraine attacks.
  • Upper‑limb spasticity: improves range of motion in post‑stroke patients.
  • Severe axillary hyperhidrosis: diminishes excessive sweating.

How It Works

  • Botulinum Toxin Type A binds to presynaptic nerve terminals at the neuromuscular junction and cleaves SNAP‑25, a protein essential for vesicle fusion. This blocks the release of acetylcholine into the synaptic cleft, preventing muscle fiber activation and resulting in localized, reversible paralysis of the targeted muscle group.

Side Effects

Botulinum Toxin Type A may cause a range of adverse reactions, most of which are related to the injection site or systemic spread of the toxin.

Common Side Effects

  • Injection site pain or bruising.
  • Localized muscle weakness.
  • Headache.
  • Dry mouth.
  • Flu‑like symptoms.
  • Transient eyelid drooping (ptosis) when used near the eyes.

Serious or Rare Side Effects

  • Dysphagia or difficulty swallowing.
  • Respiratory compromise due to spread to respiratory muscles.
  • Generalized muscle weakness.
  • Allergic reactions such as rash, itching, or anaphylaxis.
  • Vision changes including double vision.
  • Systemic botulism‑like syndrome.

Precautions & Warnings

Prior to administration, clinicians should evaluate patient history and potential risk factors.

  • Contraindication: Do not use in patients with known hypersensitivity to botulinum toxin preparations.
  • Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus.
  • Breastfeeding: Caution advised; limited data on excretion in breast milk.
  • Neuromuscular disorders: Avoid or use with extreme caution in patients with myasthenia gravis or Lambert‑Eaton syndrome.
  • Dosing: Adjust dose in pediatric patients and the elderly based on clinical response.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Botulinum Toxin Type A can interact with other agents that affect neuromuscular transmission.

Major Interactions (Avoid)

  • Aminoglycoside antibiotics (e.g., gentamicin, streptomycin): may potentiate neuromuscular blockade.
  • Curare‑type muscle relaxants: increase risk of profound paralysis.
  • Magnesium sulfate: can enhance the blocking effect.

Moderate Interactions (Monitor Closely)

  • Anticholinesterase drugs (e.g., pyridostigmine): may reduce the efficacy of the toxin.
  • Other botulinum toxin products: cumulative dosing may increase systemic exposure.
  • General anesthetics that depress neuromuscular function: monitor respiratory status.

Frequently Asked Questions

Letybo contains Botulinum Toxin Type A and is indicated for therapeutic management of disorders characterized by excessive muscle activity, such as cervical dystonia, blepharospasm, chronic migraine, upper‑limb spasticity, and severe axillary hyperhidrosis.

The toxin binds to nerve endings at the neuromuscular junction and cleaves the SNAP‑25 protein, which is essential for acetylcholine release. By blocking this neurotransmitter, the drug prevents muscle contraction, leading to temporary, localized paralysis of the targeted muscles.

The dose of Letybo is individualized by the prescribing clinician based on the specific indication, treated muscle groups, and patient characteristics. No fixed regimen is provided; the prescriber determines the appropriate amount and injection sites.

Safety data for Botulinum Toxin Type A in pregnancy and lactation are limited. Use is only recommended if the potential therapeutic benefit outweighs any possible risk to the fetus or infant, and it should be decided by a qualified healthcare professional.

To place an order, submit an enquiry on the Letybo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Letybo, like other Botulinum Toxin Type A formulations, shares the same mechanism of action and therapeutic indications. Differences may lie in formulation specifics, potency units, storage requirements, and regulatory approvals. Clinicians choose a product based on clinical experience, dosing equivalence, and local availability.

Letybo should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Maintaining the cold chain preserves potency and ensures safety until the product is prepared for administration.

Letybo is supplied as a sterile injectable solution for intramuscular injection. A qualified healthcare professional reconstitutes the vial (if required) and injects the calculated dose directly into the targeted muscle or skin area using aseptic technique.

Serious adverse events include dysphagia, respiratory compromise, generalized muscle weakness, and systemic botulism‑like syndrome. These risks are rare but require immediate medical attention if symptoms such as difficulty swallowing, breathing problems, or widespread weakness develop.

Patients with known hypersensitivity to botulinum toxin preparations, those with active infections at the injection site, or individuals with certain neuromuscular disorders (e.g., myasthenia gravis, Lambert‑Eaton syndrome) should avoid Letybo unless a specialist determines that benefits outweigh risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Botulinum Toxin Type A

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT